SAN DIEGO, June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies,...
PALO ALTO, Calif., June 4, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new...
NESS ZIONA, Israel, and HAUT-MAUCO, France, June 4, 2024 /PRNewswire/ -- NRGene (TASE: NRGN), a leading international genomics AI company, and...
Masdar City to showcase why they are the leading destination for the life sciences sector at BIO24 ABU DHABI, UAE,...
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its...
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX: IDXG), is proud to...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...
The state-of-the-art instrumentation will support and accelerate BioPharmaSpec’s clients’ efforts in successful biologics product developmentMALVERN, Pa. and ST. SAVIOUR, Jersey,...
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular...
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a...
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to...
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk...
HOUSTON, TEXAS, May 31, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma...
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks...
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple...
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study...
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...